Company: NDRA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001654954-25-005770
Chunk: 3

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
  Shares   Amount  Capital  Payable  Deficit  Equity Balance as of December 31, 2024   17.488  $-   -  $-   536,908  $53  $105,998,412  $-  $(103,438,099) $2,560,366 Fair value of vested common stock  -   -   -   -   25,305   2   145,801   -   -   145,803 Fair value of vested stock options  -   -   -   -   -   -   83,046   -   -   83,046 Stock payable towards preference dividend  -   -   -   -   -   -   -   -   -   - Net loss  -   -   -   -   -   -   -   -   (1,036,330)  (1,036,330)Balance as of March 31, 2025   17.488  $-   -  $-   562,213  $55  $106,227,259  $-  $(104,474,429) $1,752,885 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 5Table of Contents

ENDRA Life Sciences Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

  Three Months Ended  Three Months Ended   March 31,  March 31,   2025  2024 Cash Flows from Operating Activities      Net loss $(1,036,330) $(2,775,700)Adjustments to reconcile net loss to net cash used in operating activities:        Depreciation and amortization  13,786   15,300 Fixed assets write off  -   8,808 Inventory reserve  -   142,733 Stock compensation expense  83,046   317,497 Amortization of right of use assets  31,797   40,376 Changes in fair value of warrant